Recent 8-K filings for ELV

• April 22, 2026, 7:59 PM ET earnings materiality 0.78 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Elevance Health Q1 adj EPS $12.58 beats; raises FY2026 adj EPS guidance to at least $26.75

  Q1 operating revenue $49.5B (+1.5% YoY); diluted EPS $8.00, adjusted diluted EPS $12.58 (includes ~$1 non-recurring investment income).

• March 10, 2026, 7:59 PM ET other material materiality 0.70 neutral item 7.01

  Elevance Health reaffirms FY2026 adj. EPS at least $25.50, benefit expense ratio ~90.2%

  Reaffirms adjusted shareholders' earnings for FY2026 at least $25.50 per diluted share.

• March 2, 2026, 6:59 PM ET regulatory materiality 0.70 negative item 8.01

  CMS proposes sanctions suspending Elevance Medicare Advantage enrollment over risk adjustment data issues

  CMS notified Elevance of intent to impose sanctions suspending MA-PD enrollment and certain communications effective March 31, 2026 unless resolved.

• February 26, 2026, 6:59 PM ET leadership materiality 0.60 neutral item 5.02item 7.01item 9.01

  CFO Mark Kaye adds Carelon oversight; Haytaian transitions; FY2026 guidance reaffirmed

  Peter Haytaian steps down as Carelon President effective May 4, 2026; will serve as Special Advisor through Dec 31, 2026.

• January 28, 2026, 6:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  Elevance Health Q4 adj. EPS $3.33 on higher medical costs; FY2026 adj. EPS guide $25.50, down from $30.29

  Q4 2025 GAAP diluted EPS $2.47; adjusted $3.33; operating revenue $49.3B (+10% YoY).

• October 21, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Q3 revenue $50.1B (+12% YoY), GAAP EPS $5.32, adj. EPS $6.03; FY guidance reaffirmed

  Health Benefits operating revenue $42.2B (+10% YoY), operating margin 1.4%, medical membership ~45.4M.

• September 15, 2025, 7:59 PM ET debt materiality 0.60 neutral item 8.01item 9.01

  Elevance Health closes $3B multi-tranche note offering; proceeds to refinance near-term debt

  Issued $750M 4.000% notes due 2028, $750M 4.600% notes due 2032, $1,000M 5.000% notes due 2036, $500M 5.700% notes due 2055.

• July 17, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Elevance Health cuts FY2025 adjusted EPS guidance to ~$30 on elevated medical costs

  Operating revenue $49.4B (+14.3% YoY); diluted EPS $7.72, adjusted diluted EPS $8.84.

• April 22, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Elevance Health Q1 2025 revenue $48.8B (+15.4% YoY); adj. diluted EPS $11.97; reaffirms FY guidance

  Operating revenue $48.8B (+15.4% YoY); diluted GAAP EPS $9.61, adjusted diluted EPS $11.97.

• April 17, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01

  Elevance Health pre-announces Q1 2025 adjusted EPS of $11.97; reaffirms FY guidance

  Q1 GAAP EPS of $9.61, includes $2.36/share net unfavorable items; adjusted EPS $11.97.

• January 23, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Elevance Health Q4 2024 adjusted EPS $3.84, FY 2025 guidance $34.15-$34.85; dividend raised 5% to $1.71

  Q4 operating revenue $45.0B (+6% YoY); FY revenue $175.2B (+3%).

• October 31, 2024, 7:59 PM ET debt materiality 0.60 neutral item 8.01item 9.01

  Elevance Health closes $5.2B multi-tranche notes offering; proceeds for general corporate purposes

  Issued $5.2B aggregate principal across six series: 2026 (4.500%), 2030 (4.750%), 2031 (4.950%), 2035 (5.200%), 2055 (5.700%), 2064 (5.850%).

• October 17, 2024, 7:59 PM ET earnings materiality 0.85 negative item 2.02item 9.01

  Elevance Health Q3 adjusted EPS $8.37; FY2024 guidance cut to ~$33.00

  Q3 2024 operating revenue $44.7B, up $2.2B YoY; diluted EPS $4.36 GAAP, adjusted $8.37.

• July 17, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Elevance Health Q2 diluted EPS $9.85 (+26% YoY); revenue $43.2B, down $0.2B

  Adjusted diluted EPS $10.12 (+12% YoY); GAAP EPS at least $34.05 for FY2024, adjusted at least $37.20.

• May 30, 2024, 7:59 PM ET debt materiality 0.70 neutral item 8.01item 9.01

  Elevance Health closes $2.6B senior notes offering in three tranches

  Issued $600M 5.150% notes due 2029, $1B 5.375% notes due 2034, $1B 5.650% notes due 2054.

• April 18, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  Elevance Health Q1 diluted EPS $9.59 (+15.5%); raises FY2024 adj. EPS guidance to >$37.20

  Q1 operating revenue $42.3B (+0.9% YoY); diluted EPS $9.59 (+15.5%); adjusted diluted EPS $10.64 (+12.5%).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event earnings

5 positive 4 negative 17 neutral

source · ELV on sec.gov